Treatment patterns and costs of care for patients with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin in the United States: A retrospective cohort study (Q42708359)

From Wikidata

Jump to navigation Jump to search

scientific article published on 9 October 2017

Language	Label	Description	Also known as
English	Treatment patterns and costs of care for patients with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin in the United States: A retrospective cohort study	scientific article published on 9 October 2017

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

Treatment patterns and costs of care for patients with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin in the United States: A retrospective cohort study (English)

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

Hodgkin lymphoma

1 reference

based on heuristic

inferred from title

Joseph M Connors

5

object named as

Joseph M Connors

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

author name string

Shelagh M Szabo

1

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

Ishan Hirji

2

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

Karissa M Johnston

3

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

Ariadna Juarez-Garcia

4

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

language of work or name

0 references

publication date

9 October 2017

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

12

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

10

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

e0180261

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

copyright license

Creative Commons Attribution 4.0 International

9 October 2017

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Inhaled Corticosteroid Claims and Outpatient Visits After Hospitalization for Asthma Among Commercially Insured Children

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5633181

27 May 2018

Use of brentuximab vedotin as salvage therapy pre-allogeneic stem cell transplantation in relapsed/refractory CD30 positive lympho-proliferative disorders: a single centre experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5633181

27 May 2018

Using Health Care Claims Data to Assess the Prevalence of Hodgkin Lymphoma and Relapsed or Refractory Hodgkin Lymphoma in the United States

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5633181

27 May 2018

Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United States

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5633181

27 May 2018

Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5633181

27 May 2018

Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma: An updated review of published data from the named patient program

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5633181

27 May 2018

Comparison of Health Care Spending and Utilization Among Children With Medicaid Insurance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5633181

27 May 2018

Experience of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: Review of the literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5633181

27 May 2018

Economic impact of disease progression following front-line therapy in classical Hodgkin lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5633181

27 May 2018

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5633181

27 May 2018

Chemotherapy treatment patterns, costs, and outcomes of patients with gastric cancer in the United States: a retrospective analysis of electronic medical record (EMR) and administrative claims data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5633181

27 May 2018

The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5633181

27 May 2018

Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5633181

27 May 2018

Real-world impact of comparative effectiveness research findings on clinical practice.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5633181

27 May 2018

The incidence rate and economic burden of community-acquired pneumonia in a working-age population

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5633181

27 May 2018

Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5633181

27 May 2018

Classical Hodgkin's lymphoma: past, present and future perspectives

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5633181

27 May 2018

Advanced and relapsed/refractory Hodgkin lymphoma: what has been achieved during the last 50 years

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5633181

27 May 2018

Topical treatments with pimecrolimus, tacrolimus and medium- to high-potency corticosteroids, and risk of lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5633181

27 May 2018

Impact of Insurance Provider on Overall Costs in Failed Back Surgery Syndrome: A Cost Study of 122,827 Patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5633181

16 August 2018

Polypharmacy and Adherence to Adjuvant Endocrine Therapy for Breast Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5633181

16 August 2018

Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5633181

16 August 2018

How I treat relapsed and refractory Hodgkin lymphoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5633181

16 August 2018

Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5633181

16 August 2018

Medical costs associated with non-Hodgkin's lymphoma in the United States during the first two years of treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/28991893

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hodgkin lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/28991893

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PONE.0180261

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42708359&oldid=1966386665"